VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Wuliangye Yibin Co., Ltd. vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Wuliangye Yibin Co., Ltd.
000858 · Shenzhen Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Wuliangye Yibin Co., Ltd.'s moat claims, evidence, and risks.
View 000858 analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: Wuliangye Yibin Co., Ltd. leads (80 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: Wuliangye Yibin Co., Ltd. has 3 segments (76.1% in Wuliangye-branded Baijiu products); AstraZeneca PLC has 6 segments (41% in Oncology).
- Moat breadth: Wuliangye Yibin Co., Ltd. has 5 moat types across 3 domains; AstraZeneca PLC has 4 across 3.
Primary market context
Wuliangye Yibin Co., Ltd.
Wuliangye-branded Baijiu products
China baijiu market (sales revenue; producers above designated size)
China
Consumers (premium gifting/banqueting; affluent households)
Branded spirits producer and marketer
76.1%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
Wuliangye Yibin Co., Ltd. strengths
AstraZeneca PLC strengths
Segment mix
Wuliangye Yibin Co., Ltd. segments
Full profile >Wuliangye-branded Baijiu products
Oligopoly
Other liquor products (Wuliang NongXiang and other series)
Competitive
Non-liquor products (other)
Competitive
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.